GV Investment Managers

Diverge Health is a healthcare platform designed to support primary care practices in providing quality care to underserved patients. The company enhances these practices by offering a robust infrastructure that includes highly trained community health teams and administrative support. Additionally, Diverge Health integrates technology to facilitate local population health management. This comprehensive approach enables primary care providers to achieve better health outcomes for their patients while successfully navigating the shift towards value-based payment models.

Midi Health is a virtual care clinic dedicated to addressing the health needs of women, particularly during menopause and related conditions. The clinic specializes in treating issues such as depression, gynecological cancer, and menstrual problems through a clinical platform that delivers personalized care protocols. These protocols are administered by clinicians who are trained in female midlife health. Midi Health enhances its services by utilizing specialized at-home labs, providing prescription medications, supplements, and lifestyle coaching. This comprehensive approach aims to empower women to manage the challenges they face during critical stages of their lives and careers.

Oula Health, Inc. specializes in maternity care services, offering both in-clinic and home-based prenatal care. Founded in 2019 and located in Brooklyn, New York, Oula aims to transform the maternity care experience by integrating obstetrics and midwifery. The company focuses on providing a personalized and evidence-based approach to pregnancy, combining modern medical practices with a compassionate understanding of human needs. Through its innovative maternity center, Oula sets a new standard for pregnancy care that emphasizes both medical expertise and personal connection.

Midi Health is a virtual care clinic dedicated to addressing the health needs of women, particularly during menopause and related conditions. The clinic specializes in treating issues such as depression, gynecological cancer, and menstrual problems through a clinical platform that delivers personalized care protocols. These protocols are administered by clinicians who are trained in female midlife health. Midi Health enhances its services by utilizing specialized at-home labs, providing prescription medications, supplements, and lifestyle coaching. This comprehensive approach aims to empower women to manage the challenges they face during critical stages of their lives and careers.

Caraway is a digital healthcare company for college women+ that provides integrated mental, reproductive and physical healthcare services. Built with students for students, Caraway arms women+ with the first personalized, equitable and digitally-accessible care solution that prioritizes their needs and concerns. With an unprecedented need for mental health resources and new barriers and persistent inequities in women’s+ health, Caraway provides access to trusted, holistic, and compassionate healthcare so women+ can get the care they need when they need it.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors affected by dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach that emphasizes personalized care. Rippl Care utilizes innovative technology to deliver comprehensive support, allowing seniors to receive care through various channels, including phone, online, and in-person visits. By focusing on empowering clinicians and adopting a new care model, Rippl Care aims to enhance the quality of life for elderly individuals suffering from conditions such as Alzheimer's disease.

Invetx, Inc. is a biotechnology company focused on developing protein-based therapeutics for animal health care and veterinary medicine. Based in Boston, Massachusetts, Invetx's team comprises veterinary scientists and clinicians dedicated to discovering and creating biotherapeutics for both pets and farm animals. The company aims to enhance health outcomes in the animal health industry by leveraging biopharma technologies, supported by a network of experts in animal and human health. Through its innovative platform, Invetx is committed to advancing a portfolio of therapies and technologies designed to improve animal care and well-being.

Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

Waltz Health is focused on enhancing the pharmaceutical supply chain by collaborating with consumers, payers, and pharmacies to develop innovative, technology-driven solutions for pricing, distribution, and prescription of medications. The company creates AI-driven marketplaces that aim to reduce costs and provide valuable insights for users, facilitating informed decision-making in prescription care. By offering consumer tools designed to empower individuals and help payers manage their pharmacy benefits, Waltz Health strives to improve accessibility and affordability in the healthcare sector.

Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the platform integrates with health plans and systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. By facilitating connections among physicians, mental health providers, and insurers, Quartet Health enhances access to mental health care that aligns with patients' preferences and clinical needs, while also supporting tools for patient self-management. This approach not only improves the quality of care but also contributes to lowering healthcare costs for patients.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw. CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, now one of the most important biomarkers in the quest to improve human health. Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease. A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.

Patina is a healthcare provider focused on enhancing the aging experience for older adults and their families. The company has developed a care model that prioritizes the unique needs and values of this demographic. By offering personalized and on-demand services, Patina aims to create a healthcare experience that is both human-centered and supportive. This approach allows families to actively participate in the care of their loved ones, ensuring that older adults receive the attention and respect they deserve as they navigate the challenges of aging. Patina's mission is to empower individuals to live their best lives and maintain their dignity as they age.

Favor is a direct-to-consumer service for women and people who menstruate, that’s on a mission to make healthcare more accessible by building a digital health platform that closes racial, gender and socioeconomic gaps in our healthcare system. Favor is the easiest way for women and people who menstruate to address their sexual health and overall wellbeing, regardless of where they live or if they’re covered by health insurance–making Favor an affordable, accessible telehealth provider.

Leyden Labs is focused on developing intranasal products that aim to protect individuals from respiratory viruses, including those in the influenza and coronavirus families. The company's innovative approach targets common characteristics across various viral families, allowing for simultaneous protection against multiple viruses rather than just specific variants, as is the case with traditional vaccines. This strategy seeks to empower individuals to safeguard themselves from infections and reduce the transmission of these diseases. Leyden Labs is driven by a team of experienced biotechnology professionals who are committed to advancing solutions that alleviate the impact of respiratory viruses on public health.

Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration, enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies.

Locanabio, Inc. is a biotechnology company based in San Diego, California, founded in 2016. It specializes in developing RNA-targeted gene therapies aimed at treating a range of underserved diseases, particularly in the areas of neuromuscular, neurodegenerative, and retinal conditions. The company's innovative platform focuses on modifying disease-causing RNA, allowing for the identification and correction of specific RNA sequences associated with rare genetic disorders. This approach distinguishes Locanabio's therapies from traditional DNA-targeted methods, offering a unique solution for patients with severe and challenging health issues. The company, which rebranded from Locana, Inc. in July 2020, is dedicated to advancing therapeutic candidates that address significant medical needs.

PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.

Aledade, Inc. is a health technology company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and based in Bethesda, Maryland, Aledade partners with independent primary care providers to offer a comprehensive suite of services, including data analytics, guided workflows, regulatory expertise, and payer relationships. The company also provides 360° practice support, workflow optimization, and assistance with ACO governance and contracting. By leveraging its technology platform, Aledade enables physicians to access integrated data and insights that help improve patient care, reduce costs, and maintain the autonomy of independent practices. Its tailored solutions cater to a diverse range of healthcare providers, including small practices, large practices, community health centers, and multispecialty groups.

CareBridge is a technology and services provider based in Nashville, Tennessee, dedicated to improving the lives of individuals with physical, intellectual, or developmental disabilities who receive home and community-based services. Founded in 2009, the company specializes in assisting health plans and states by offering comprehensive solutions such as electronic visit verification, data aggregation, and 24/7 clinical support. CareBridge focuses on ensuring that Medicaid recipients, as well as those dually eligible for Medicare and Medicaid, receive the necessary services, equipment, and support to maintain their independence at home. By facilitating continuous communication between patients, their families, and caregivers, CareBridge enhances the quality of care and promotes a supportive environment for those they serve.

Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration, enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies.

Locanabio, Inc. is a biotechnology company based in San Diego, California, founded in 2016. It specializes in developing RNA-targeted gene therapies aimed at treating a range of underserved diseases, particularly in the areas of neuromuscular, neurodegenerative, and retinal conditions. The company's innovative platform focuses on modifying disease-causing RNA, allowing for the identification and correction of specific RNA sequences associated with rare genetic disorders. This approach distinguishes Locanabio's therapies from traditional DNA-targeted methods, offering a unique solution for patients with severe and challenging health issues. The company, which rebranded from Locana, Inc. in July 2020, is dedicated to advancing therapeutic candidates that address significant medical needs.

Favor is a direct-to-consumer service for women and people who menstruate, that’s on a mission to make healthcare more accessible by building a digital health platform that closes racial, gender and socioeconomic gaps in our healthcare system. Favor is the easiest way for women and people who menstruate to address their sexual health and overall wellbeing, regardless of where they live or if they’re covered by health insurance–making Favor an affordable, accessible telehealth provider.

Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw. CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, now one of the most important biomarkers in the quest to improve human health. Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease. A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative immunotherapeutics and vaccines aimed at treating and preventing infectious diseases and cancer. The company's proprietary platform includes modified simian adenoviral vectors known as ChAdOx1 and ChAdOx2, as well as a Modified Vaccinia Ankara (MVA) boost vector, both of which have established safety profiles and do not replicate in humans. This platform has shown to elicit significantly higher levels of CD8+ T cells compared to other technologies. Barinthus Biotherapeutics maintains a diverse pipeline that includes both clinical and preclinical therapeutic programs addressing solid tumors and viral infections, alongside prophylactic vaccine candidates. The company has also collaborated on the development of a COVID-19 vaccine in partnership with the University of Oxford, which has been licensed for global use.

Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the platform integrates with health plans and systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. By facilitating connections among physicians, mental health providers, and insurers, Quartet Health enhances access to mental health care that aligns with patients' preferences and clinical needs, while also supporting tools for patient self-management. This approach not only improves the quality of care but also contributes to lowering healthcare costs for patients.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for solid tumors and hematological malignancies. Founded in 2014 and based in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to identify and develop innovative antibody therapeutics. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase I clinical trials. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, and has completed a Phase 1 dose escalation study. Additionally, CTX-8371, another bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Compass Therapeutics aims to engage the immune system effectively to advance its therapeutic offerings.

Clover Health Inc. is a health insurance provider focused on offering Medicare Advantage plans to senior citizens, primarily based in New Jersey. Founded in 2014 and headquartered in San Francisco, the company also operates in several other states, including Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health employs a Preferred Provider Organization (PPO) platform designed to enhance the quality of care for its members and their physicians. Utilizing patient-centered analytics and a dedicated care management team, Clover aims to identify potential health risks and deliver preventive care, which helps in reducing avoidable healthcare expenditures and managing chronic diseases. The company’s proprietary software platform, Clover Assistant, equips physicians with personalized insights for early detection and management of chronic conditions. Clover Health operates mainly through its Insurance segment, which includes its PPO and Health Maintenance Organization (HMO) plans, while also participating in the ACO REACH Model in its Non-Insurance segment.

Aledade, Inc. is a health technology company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and based in Bethesda, Maryland, Aledade partners with independent primary care providers to offer a comprehensive suite of services, including data analytics, guided workflows, regulatory expertise, and payer relationships. The company also provides 360° practice support, workflow optimization, and assistance with ACO governance and contracting. By leveraging its technology platform, Aledade enables physicians to access integrated data and insights that help improve patient care, reduce costs, and maintain the autonomy of independent practices. Its tailored solutions cater to a diverse range of healthcare providers, including small practices, large practices, community health centers, and multispecialty groups.

Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the platform integrates with health plans and systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. By facilitating connections among physicians, mental health providers, and insurers, Quartet Health enhances access to mental health care that aligns with patients' preferences and clinical needs, while also supporting tools for patient self-management. This approach not only improves the quality of care but also contributes to lowering healthcare costs for patients.

Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw. CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, now one of the most important biomarkers in the quest to improve human health. Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease. A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.

PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.

Oscar Health is a health insurance company that offers a range of plans for individuals, families, and small groups, as well as Medicare Advantage options for adults aged 65 and older. Founded in 2012 by Joshua Kushner, Kevin Nazemi, and Mario Schlosser, the company is headquartered in New York City. Oscar Health employs technology and data-driven solutions to enhance the healthcare experience, providing virtual care, doctor support, and appointment scheduling services. Its plans are available in select regions of New York, New Jersey, California, and Texas, catering to those who do not receive employer-sponsored health insurance.

Spruce Health, Inc. is a healthcare technology company based in San Francisco, California, that offers an interactive mobile application designed to connect patients with dermatologists for the diagnosis and treatment of various skin conditions, including acne, eczema, and psoriasis. Founded in 2013, Spruce Health aims to streamline the healthcare experience by providing a platform that enhances communication between patients and physicians. The company focuses on making healthcare more accessible and affordable, eliminating the common frustrations of long wait times and unexpected costs. By leveraging software to improve the patient-physician relationship, Spruce Health seeks to enhance the quality of care, patient satisfaction, and overall efficiency in healthcare delivery.

SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.